Evidence map›Paper›PMID 31690716›Full record

ArticleNature communications2019

The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35.

Pei Y Liu, Andrew E Tee, Giorgio Milazzo, Katherine M Hannan, Jesper Maag, Sujanna Mondal, Bernard Atmadibrata, Nenad Bartonicek, Hui Peng, Nicholas Ho and 25 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 99 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Combination of clinical parameters andQuantitative imaging in medicine and surgery · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 11 institutions in 6 countries.

Pei Y LiuChildren's Cancer Institute Australia for Medical Research, Randwick, NSW, 2031, Australia.ORCID http://orcid.org/0000-0002-4408-6008
Andrew E TeeChildren's Cancer Institute Australia for Medical Research, Randwick, NSW, 2031, Australia.
Giorgio MilazzoDepartment of Pharmacy and Biotechnology, University of Bologna, 40126, Bologna, Italy.ORCID http://orcid.org/0000-0002-1930-4763
Katherine M HannanAustralian Cancer Research Foundation Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
Jesper MaagGarvan Institute of Medical Research, Sydney, Darlinghurst, NSW, 2010, Australia.ORCID http://orcid.org/0000-0002-2578-8872
Sujanna MondalChildren's Cancer Institute Australia for Medical Research, Randwick, NSW, 2031, Australia.ORCID http://orcid.org/0000-0002-2863-2726
Bernard AtmadibrataChildren's Cancer Institute Australia for Medical Research, Randwick, NSW, 2031, Australia.
Nenad BartonicekGarvan Institute of Medical Research, Sydney, Darlinghurst, NSW, 2010, Australia.
Hui PengAdvanced Analytics Institute, University of Technology Sydney, Broadway, NSW, 2007, Australia.
Nicholas HoChildren's Cancer Institute Australia for Medical Research, Randwick, NSW, 2031, Australia.ORCID http://orcid.org/0000-0001-9843-0866
Chelsea MayohChildren's Cancer Institute Australia for Medical Research, Randwick, NSW, 2031, Australia.
Roberto CiaccioDepartment of Pharmacy and Biotechnology, University of Bologna, 40126, Bologna, Italy.ORCID http://orcid.org/0000-0003-3024-9205
Yuting SunChildren's Cancer Institute Australia for Medical Research, Randwick, NSW, 2031, Australia.
Michelle J HendersonChildren's Cancer Institute Australia for Medical Research, Randwick, NSW, 2031, Australia.
Jixuan GaoChildren's Cancer Institute Australia for Medical Research, Randwick, NSW, 2031, Australia.
Celine EveraertCenter for Medical Genetics Ghent, Ghent University, Ghent, Belgium.ORCID http://orcid.org/0000-0001-7772-4259
Amy J HulmeChildren's Cancer Institute Australia for Medical Research, Randwick, NSW, 2031, Australia.ORCID http://orcid.org/0000-0001-7700-3486
Matthew WongChildren's Cancer Institute Australia for Medical Research, Randwick, NSW, 2031, Australia.ORCID http://orcid.org/0000-0003-2680-961X
Qing LanDepartment of Neurosurgery, the Second Affiliated Hospital of Soochow University, 215004, Suzhou, Jiangsu, P.R. China.
Belamy B CheungChildren's Cancer Institute Australia for Medical Research, Randwick, NSW, 2031, Australia.ORCID http://orcid.org/0000-0001-8784-860X
Leming ShiState Key Laboratory of Genetic Engineering, School of Life Sciences and Human Phenome Institute, Fudan University, 201203, Shanghai, China.
Jenny Y WangChildren's Cancer Institute Australia for Medical Research, Randwick, NSW, 2031, Australia.ORCID http://orcid.org/0000-0002-1325-7943
Thorsten SimonDepartment of Pediatric Oncology and Hematology, University Hospital, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0002-3425-8451
Matthias FischerDepartment of Experimental Pediatric Oncology, University Hospital, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0003-1363-1242
Xu D ZhangSchool of Medicine and Public Health, Priority Research Centre for Cancer Research, University of Newcastle, Callaghan, NSW, 2308, Australia.ORCID http://orcid.org/0000-0001-9457-8003
Glenn M MarshallChildren's Cancer Institute Australia for Medical Research, Randwick, NSW, 2031, Australia.
Murray D NorrisChildren's Cancer Institute Australia for Medical Research, Randwick, NSW, 2031, Australia.ORCID http://orcid.org/0000-0002-0632-4589
Michelle HaberChildren's Cancer Institute Australia for Medical Research, Randwick, NSW, 2031, Australia.ORCID http://orcid.org/0000-0003-2036-8817
Jo VandesompeleCenter for Medical Genetics Ghent, Ghent University, Ghent, Belgium.ORCID http://orcid.org/0000-0001-6274-0184
Jinyan LiAdvanced Analytics Institute, University of Technology Sydney, Broadway, NSW, 2007, Australia.ORCID http://orcid.org/0000-0003-1833-7413
Pieter MestdaghCenter for Medical Genetics Ghent, Ghent University, Ghent, Belgium.ORCID http://orcid.org/0000-0001-7821-9684
Ross D HannanAustralian Cancer Research Foundation Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.ORCID http://orcid.org/0000-0002-2166-4493
Marcel E DingerGarvan Institute of Medical Research, Sydney, Darlinghurst, NSW, 2010, Australia.ORCID http://orcid.org/0000-0003-4423-934X
Giovanni PeriniDepartment of Pharmacy and Biotechnology, University of Bologna, 40126, Bologna, Italy. giovanni.perini@unibo.it.
Tao LiuChildren's Cancer Institute Australia for Medical Research, Randwick, NSW, 2031, Australia. tliu@ccia.unsw.edu.au.ORCID http://orcid.org/0000-0001-6244-7316
Children's Cancer Institute Australia · AUGhent University Hospital · BEUniversity of Bologna · ITAustralian National University · AUMemorial Sloan Kettering Cancer Center · USUniversity of Cologne · DEUniversity of Technology Sydney · AUFudan University · CNGarvan Institute of Medical Research · AUSoochow University · CNUniversity of Newcastle Australia · AU

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Eradication of MYCN-amplified neuroblastoma by targeting the interaction between a long noncoding RNA and its binding proteinR21CA226959 · NCI · UNIVERSITY OF NEW SOUTH WALES · PI LIU, TAO · 2018 to 2019
$246k
NCI NIH HHS P30 CA008748NCI NIH HHS R21 CA226959
6 · The paper itself

Abstract

The majority of patients with neuroblastoma due to MYCN oncogene amplification and consequent N-Myc oncoprotein over-expression die of the disease. Here our analyses of RNA sequencing data identify the long noncoding RNA lncNB1 as one of the transcripts most over-expressed in MYCN-amplified, compared with MYCN-non-amplified, human neuroblastoma cells and also the most over-expressed in neuroblastoma compared with all other cancers. lncNB1 binds to the ribosomal protein RPL35 to enhance E2F1 protein synthesis, leading to DEPDC1B gene transcription. The GTPase-activating protein DEPDC1B induces ERK protein phosphorylation and N-Myc protein stabilization. Importantly, lncNB1 knockdown abolishes neuroblastoma cell clonogenic capacity in vitro and leads to neuroblastoma tumor regression in mice, while high levels of lncNB1 and RPL35 in human neuroblastoma tissues predict poor patient prognosis. This study therefore identifies lncNB1 and its binding protein RPL35 as key factors for promoting E2F1 protein synthesis, N-Myc protein stability and N-Myc-driven oncogenesis, and as therapeutic targets.

Indexed as

AnimalsCarcinogenesisCell Line, TumorCell ProliferationCell SurvivalE2F1 Transcription FactorFemaleGene Expression Regulation, NeoplasticGTPase-Activating ProteinsHumansMice, Inbred BALB CMice, NudeNeuroblastomaN-Myc Proto-Oncogene ProteinPrognosisProtein BiosynthesisDEPDC1B protein, humanE2F1 protein, humanE2F1 Transcription FactorGTPase-Activating ProteinsMYCN protein, humanN-Myc Proto-Oncogene ProteinRibosomal ProteinsRNA, Long NoncodingRPL35A protein, human

Identifiers

PMID31690716
PMCPMC6831662
OpenAlexW2982755113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.